Journal Watch

karenskjeiKaren L. Skjei, M.D.
Assistant Professor,
Department of Neurology Co-Director,
Epilepsy Surgery Program Director,
Epilepsy Monitoring Unit,
Norton Children's Hospital

Dr. Karen Skjei is an assistant professor of Neurology and Pediatrics at the University of Louisville. She completed her undergraduate studies at Duke University, and her medical education at the University of California at San Francisco School of Medicine. She completed a residency in Pediatrics and a fellowship in Child and Adolescent Neurology at the Mayo Clinic in Rochester, New York. She completed a fellowship in Neurophysiology and Epilepsy at the Children’s Hospital of Philadelphia. Dr Skjei is currently Editor of the ICNApedia Journal Watch

92 results - showing 21 - 30
1 2 3 4 5 6 7 8 9 10
Ordering
 
0.0
 
0.0 (0)
Karen L Skjei
Karen L Skjei
Updated January 06, 2020 11867 0
Pediatric neurology 101 (2019): 18-25.
 
0.0
 
5.0 (1)
William Qubty
William Qubty
Updated December 02, 2019 2569 0
Objective To provide updated evidence-based recommendations for migraine prevention using pharmacologic treatment with or without cognitive behavioral therapy in the pediatric population. Methods The authors systematically reviewed literature from January 2003 to August 2017 and developed practice recommendations using the American Academy of Neurology 2011 process, as amended. Results Fifteen Class I–III studies on migraine prevention in children and adolescents met inclusion criteria. There is insufficient evidence to determine if children and adolescents receiving divalproex, onabotulinumtoxinA, amitriptyline, nimodipine, or flunarizine are more or less likely than those receiving placebo to have a reduction in headache frequency. Children with migraine...
 
0.0
 
0.0 (0)
SC Sireesha Chinthaparthi Updated February 22, 2020 30193 0
Pediatric Neurology 2018: 78, 55-60
 
0.0
 
0.0 (0)
DF Daniel Freedman Updated February 22, 2020 20275 0
Pediatric Neurology 2019: 97, 56-63
 
0.0
 
0.0 (0)
Karen L Skjei
Karen L Skjei
Updated December 01, 2019 30523 0
Indian Pediatrics 2019: 56, 643-646
Abstract Objective: To compare the efficacy and safety of intravenous Levetiracetam and Phenobarbitone in the treatment of neonatal seizures. Design: Open labelled, Randomized controlled trial. Setting: Level III Neonatal Intensive Care Unit (NICU). Participants: 100 neonates (0-28 days) with clinical seizures. Intervention: If seizures persisted even after correction of hypoglycemia and hypocalcemia, participants were randomized to receive either Levetiracetam (20 mg/kg) or Phenobarbitone (20 mg/kg) intravenously. The dose of same drug was repeated if seizures persisted (20 mg/kg of Levetiracetam or 10 mg/kg of Phenobarbitone) and changeover to other drug occurred if the seizures persisted even...
 
0.0
 
0.0 (0)
ICNA
ICNA
May 26, 2019 948 0
Lancet 2019
Background Phenytoin is the recommended second-line intravenous anticonvulsant for treatment of paediatric convulsive status epilepticus in the UK; however, some evidence suggests that levetiracetam could be an effective and safer alternative. This trial compared the efficacy and safety of phenytoin and levetiracetam for second-line management of paediatric convulsive status epilepticus.
 
0.0
 
0.0 (0)
Biju Hameed
Biju Hameed
Updated May 25, 2019 897 0
Neurology 92 (15):e1698-e1708
Liberato and colleagues retrospectively analyzed brain magnetic resonance imaging (MRI) scans for brain lesion volume, Loes score, and growth over time in a cohort of boys biochemically or genetically diagnosed with adrenoleukodystrophy. Demographic data, genotype information, biochemical data, follow-up intervals, and brain lesion characteristics were recorded in all MRI scans. White matter changes were scored using the Loes MRI severity scoring system, and lesions were subdivided into 5 patterns based on primary anatomic distribution.
 
0.0
 
0.0 (0)
Biju Hameed
Biju Hameed
Updated May 25, 2019 535 0
Epilepsia 60 (5):872-884
Modest improvements in IQ in children with epilepsy who underwent epilepsy surgery, a finding which was not seen in children with severe epilepsy who did not undergo surgery. 
 
0.0
 
0.0 (0)
ICNA
ICNA
Updated June 11, 2018 1507 0
The Lancet May 23, 2018
Paolo Curatolo, David N Franz, John A Lawson, Zuhal Yapici, Hiroko Ikeda, Tilman Polster, Rima Nabbout, Petrus J de Vries, Dennis J Dlugos, Jenna Fan, Antonia Ridolfi, Diana Pelov, Maurizio Voi, Jacqueline A French https://doi.org/10.1016/S2352-4642(18)30099-3 Background Epilepsy occurs in 70–90% of patients with tuberous sclerosis complex. We aimed to assess the efficacy and safety of adjunctive everolimus for treatment-refractory seizures associated with tuberous sclerosis complex in paediatric patients enrolled in the EXIST-3 trial, a double-blind, placebo-controlled, randomised, phase 3 study. Methods This post-hoc analysis focused on paediatric patients...
 
0.0
 
0.0 (0)
ICNA
ICNA
Updated July 23, 2018 1766 0
N Engl J Med 2018; 378:1888-1897
BACKGROUND Cannabidiol has been used for treatment-resistant seizures in patients with severe early-onset epilepsy. We investigated the efficacy and safety of cannabidiol added to a regimen of conventional antiepileptic medication to treat drop seizures in patients with the Lennox–Gastaut syndrome, a severe developmental epileptic encephalopathy.  
92 results - showing 21 - 30
1 2 3 4 5 6 7 8 9 10

pleasedonate